FDA fast-tracks psychedelic drug research following Trump executive order
CNBC
—
It's a big shift toward supporting psychedelic-based medicines for treatment-resistant depression, PTSD and substance use disorders, the FDA said.
- U.S. FDA plans ultra-fast review of three psychedelic drugs following Trump directive CTV News —
- US FDA plans ultra-fast review of 3 psychedelic drugs after Trump directive South China Morning Post —
- FDA grants quick review for 3 psychedelic drug trials NBC News —
- US FDA moves to fast-track psychedelic drugs after Trump order - Reuters Reuters —
- FDA plans fast review of 3 psychedelic drugs following Trump directive Boston Globe —